news 
Title: InnovationRx: A Patent Fight Over the World’s Top-Selling Drug
The world of biotech and pharmaceuticals is abuzz with a recent development regarding the top-selling drug, Merck’s Keytruda. As reported in Forbes’ recent article, it seems that Akeso, a Chinese biotech firm, has won approval for its own version of the drug in China. This move has significant implications for the global health market and may have far-reaching consequences.
The real news here lies not in Akeso’s approval, but rather in the fact that Summit Therapeutics has entered into an agreement with the company to develop this challenger drug in the United States. This deal could potentially disrupt the status quo of Keytruda as the world’s top-selling medication.
But what does this mean for patients?
Source: https://www.forbes.com/sites/innovationrx/2025/04/30/innovationrx-a-patent-fight-over-the-worlds-top-selling-drug/
